fda compounding semaglutide crackdown news today The FDA's GLP-1 Continues: What to Know Compounded Semaglutide & Tirzepatide 2025:

Conclusion The abdomen, front or outer thigh, and back or outer upper arm are approved GLP1 injection areas, but the best choice depends on comfort, visibility, reach, and your ability to rotate sites consistently

And, in addition to sending satiety signals to your brain telling you youre full, semaglutide has been shown to reduce your appetite and even your desire for certain foods

Figure 7: Photograph of Leonard Thompson in 1930 together with (A) his medical record and (B) chart of his blood sugar levels from December 1921 to January 1922 (credit:Thomas Fisher Rare Book Library, University of Toronto)

Its dual-receptor design (GIP + GLP-1) produces strong results, but the absence of glucagon receptor activation limits its ceiling